Recently described forkhead box protein 3 (FoxP3) transcription factor is a key molecule in CD41 CD25hi1 T-cell characterization. Invariant NK T (iNKT) cells are also characterized as regulatory cells modulating the immune response by rapidly producing T h 1 and T h 2 cytokines. We aimed to analyze cellular markers important in regulatory features of human iNKT cells and to study their role in functional assays. iNKT cells were single cell sorted from peripheral mononuclear cells of healthy individuals after immunostaining of invariant TCR a-chain. We found FoxP3 expression in human iNKT clones. Randomly selected iNKT cell clones (CD41, double negative, CD81) expressed FoxP3 mRNA and protein at different levels upon stimulation as supported by various approaches. FoxP3 mRNA and protein expression was detected in unstimulated iNKT cells as well. Furthermore, different stimulations changed the FoxP3 expression in iNKT cells over time and the most dramatic changes were observed upon anti-CD3 stimulation. Both the supernatant of iNKT cells and iNKT cells themselves exerted similar stimulation effects on PBMC proliferation in functional assays and these stimulations showed a negative correlation with FoxP3 expression. Our data indicate that the FoxP3 expression in iNKT cells may be a key transcriptional factor in controlling the regulatory function of the iNKT cells.
Introduction
The main role of the immune system is to protect individuals from pathogens and maintain self-integrity. In the thymus, potentially self-reactive T cells are deleted, resulting in a peripheral T-cell repertoire that is largely self-tolerant. Nevertheless, some self-reactive T cells are present in most individuals. In contrast, autoimmune diseases only occur infrequently, which indeed suggests that autoreactive T cells are controlled in the periphery. Several mechanisms participate in peripheral tolerance such as deletion, anergy and ignorance (1, 2) . In addition, there is now emerging evidence for the existence of more 'active' tolerance mechanisms involving immune-regulatory cells. Various types of regulatory T cells (Treg cells), such as cd T cells, NK T cells (NKT), CD8+ and CD4+ T cells, have been described (3) (4) (5) (6) . CD4+ Treg cells can be further divided into naturally occurring CD4+ CD25hi+-regulatory T cells (nTreg) and induced regulatory T cells (iTreg) such as Tr1 cells and T h 3 cells that secrete IL-10 and transforming growth factor-b (TGF-b) 1 (7) .
Tregs are typically characterized as CD4+ T cells by constitutive surface expression of the IL-2 receptor a-chain (CD25). In addition to CD4 and CD25, characteristic markers for Tregs include CTLA-4, glucocorticoid-induced tumor necrosis factor receptor, programmed cell death 1 (PD-1), neuropilin-1 (Nrp1), CD103 and CD127 (5, 6, 8) . Recently, the transcription factor, forkhead box protein 3 (FoxP3) has been considered as a key component for Treg development and function (9, 10) . In humans, none of these markers indentify the Tregs unequivocally.
The forkhead gene family is a diverse group of winged helix transcription factors, which play critical roles in biological processes. FoxP3 is currently the most widely studied forkhead family member in immunology. These transcription factors control a wide range of biological processes, including lineage commitment and differentiation (11) .
The essential role of FoxP3 in humans in maintaining immunologic homeostasis via Tregs has been confirmed in families who exhibit multi-organ autoimmune syndromes. Mutations in FoxP3 result in a syndrome consisting of immune dysregulation, polyendocrinopathy and enteropathy with X-linked inheritance (IPEX) and most of the affected cases develop diarrhea, type I diabetes mellitus, thyroid abnormalities, recurrent infections and hemolytic anemia (12) .
NK T cells represent a minor population of T cells characterized by the co-expression of NK cell markers and the TCR. NKT cells are a heterogenous population consisting of the most extensively characterized CD1d-restricted invariant NKT (iNKT) cells (type I/classical NKT), CD1d-restricted noninvariant (type II/non-classical NKT) and CD1d-independent (type III) NKT cells (13) (14) (15) (16) .
In mice, most NKT cells express Va14-Ja18 TCR a-chain paired with Vb8.2, Vb2 or Vb7 chains, while in humans, one homologous population of NKT cells co-expresses Va24-JaQ (Va24-Ja18) paired with Vb11 chain in most cases (17, 18) . These NKT cells express limited diversity of TCR a-chains and are termed iNKT cells. In mice, the majority of iNKT cells express CD4, the remaining cells express neither CD4 nor CD8. However, in humans, there is a small subset of CD8+ iNKT cells. Human CD4-CD8-or double-negative (DN) iNKT cells mainly produce T h 1-type cytokines, while CD4+ iNKT cells produce both T h 1-and T h 2-type cytokines (16) . Tregs and iNKT cells have been extensively studied, but usually as independent regulators of the immune response because of their apparently unrelated mechanisms of activation and suppressor activity (19, 20) .
Primary differences between Tregs and iNKT cells are that Tregs recognize peptides presented by MHC class II molecules, while most NKT cells react to glycolipid antigens presented by the CD1d (19) . Additionally, Tregs have a diverse TCR repertoire; in contrast, iNKT cells have a significantly restricted TCR repertoire. Furthermore, Tregs react to a wide variety of autologous or foreign peptides, whereas iNKT cells are specific for a limited set of glycolipid antigens. The most commonly used antigen for iNKT cell stimulation is the a-galactosyl-ceramide (a-GalCer), while the endogenous antigen of iNKT cells was recently described as isoglobotrichexosyl-ceramide (iGb3) (21) . However, this was challenged with conflicting results (22, 23) . Exogenous antigens are glycosyl-ceramides isolated from Sphingomonas bacteria (21, 24, 25) . There is evidence from experimental autoimmune encephalomyelitis disease model suggesting that intentional activation of iNKT cells by a-GalCer is required to elicit their regulatory function (26) .
Unless there is more understanding of the factors that naturally lead to iNKT cell activation and their mechanism of their regulatory function, the basis for their involvement in many autoimmune diseases will remain elusive. There are a great number of studies investigating the role of NKT cells in autoimmune disease pathogenesis, tumor surveillance and host defense (17, (27) (28) (29) (30) .
We hypothesized that regulatory function of the iNKT cells is similar to the Tregs and studied established Treg cell markers in cultured human iNKT cell populations. We found FoxP3 expression in cultured iNKT cell clones on the mRNA level. Subsequently, we confirmed its expression on both the mRNA and protein levels. We investigated whether FoxP3 was expressed-similarly as in Treg cells-upon stimulation and how it was related to cytokine production of the iNKT cells and what its functional relevance was to iNKT cell activity.
Materials and methods

PBMC samples
PBMCs were obtained from fresh blood of healthy individuals without personal or family history of autoimmune disease (n = 70) by Ficoll (Amersham Pharmacia Biotech Europe, Uppsala, Sweden) gradient centrifugation following standard protocol. The PBMCs were frozen in Human AB serum (Omega, Tarzana, CA, USA) with 10% DMSO (SigmaAldrich, St Louis, MO, USA) and stored at -80°C. Studies were approved by Joslin Institutional Review Board and Regional Research Ethics Committee of the Faculty of Medicine at the University of Pé cs (3349/2009-1) and written consent was obtained from healthy blood donors.
Generation of iNKT cell clones
PBMCs were washed with PBS and stained with 6B11-FITC (1:20 dilution; BD Biosciences Pharmingen, San Diego, CA, USA) and a-Va24-PE (1:50 dilution; Beckman Coulter, Fullerton, CA, USA) antibodies (31) (32) (33) (34) . Both antibody preparations were dialyzed in sterile PBS using Slide-A-Lyzer Dialysis cassette (Pierce, Rockford, IL, USA). The staining media consisted of PBS and 0.5% heat-inactivated Human AB serum (Omega). Ten million cells in 0.5 ml staining media were incubated on ice for 30 min with labeled antibodies. 
RNA extraction
RNA extraction was performed using RNAEasy Microkitâ (Qiagen GmbH, Hilden, Germany) or TRIzol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's guidelines (including DNase I digestion) from iNKT clones, sorted iNKT samples, total PBMC, Jurkat, Raji and THP-1 cell lines. Isolated RNA was re-suspended in DEPC-treated water, quantified at 260 nm and the quality of total RNA was confirmed by 1% agarose gel analysis.
Reverse transcription-PCR and sequencing
The cDNA was produced from total RNA with Superscript II reverse transcriptase (Invitrogen) in 25 ll reactions with random hexamers following manufacturer's protocol. The resulting cDNA was stored at À20°C. Primers (Table 1) to confirm the invariant a-chain were designed around the V-J-C rearrangement region of TCR (35, 36) .
PCR was performed on the cDNA using Platinumâ Taq DNA polymerase (Invitrogen) in 50 ll reactions according to the manufacturer's protocol. Final primer concentrations were 10 lM to amplify DNA. The annealing temperature was 52°C. The cDNA quality was confirmed in all cases using GAPDH as housekeeping gene product. Amplified DNA was visualized on 2% agarose gels containing 1 lg ml À1 ethidium bromide run in 0.5 3 TBE buffer (45 mM Tris-borate; 1 mM EDTA, pH 8.0). TrackIt 100-bp DNA ladder marker (Invitrogen) was run in parallel. DNA templates were recovered from PCR products with a QIAquickTM PCR purification kit (Qiagen GmbH) and quality was confirmed by 1% agarose gel analysis before sequencing. Templates were sequenced at ABI3100 sequencer (Applied Biosystems, Carlsbad, CA, USA) from both sides with forward and reverse primers.
Quantitative real-time PCR analysis of FoxP3 expression
FoxP3 RNA expression was measured by real-time PCR using SyBRGreen MasterMix (Applied Biosystems) with an ABI Prism 7000 instrument. The iNKT clone cDNAs were used as a template for the amplification reactions. All samples were tested in triplicate. Primers were custom designed considering exon-intron boundaries ( Table 1 ). The thermal profile started at 95°C for 10 min, 40 cycle of 0.15 s at 95°C, 1 min at 60°C and 1 min at 72°C.
Flow cytometry of iNKT cells (clones and unstimulated mononuclear cells)
Cultured iNKT cells were collected and washed twice with PBS before staining and then cells were labeled with antibodies specific for surface molecules in staining solution: a-CD3-APC a-CD4-PE, a-CD4-PerCP, a-CD8-PECy5, a-CD25-PE, a-CD25-PECy5 (all from BD Biosciences). Unstimulated iNKT and Treg cells from peripheral blood samples were stained for surface markers (6B11-FITC, a-CD4-PerCP, a-CD3-APC), after the incubation period erythrocytes were lysed (BD FACS Lysing Solution). Intracellular FoxP3 staining was done according to the manufacturer's protocols (clone PCH101, clone 236A/E7; eBioscience, San Diego, CA, USA) along with appropriate isotype control antibodies.
FoxP3 protein detection by western blot in iNKT cells
Proteins from NKT clones, PBMC, HepG2, K562 cell lines were isolated by RIPA lysis buffer [50 mM Tris-HCl, pH: 8.0, 150 mM NaCl, 1% (v/v) NP-40, 0.5% (w/v) Na-deoxycholate, 5 mM EDTA, 0.1% SDS]. The protein concentrations were measured by BCA Protein Assay kit (Pierce). Proteins were separated by SDS-PAGE on 10% polyacrylamide gels, topped by a 4% stacking gel according to Laemmli (37) using Mini-Protean 3 apparatus (Bio-Rad, Hercules, CA, USA). Separated proteins were transferred to nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany) in blotting buffer at 4°C for 2 h. The efficiency of blotting was monitored by staining the membranes with Ponceau S (Fisher Scientific, Pittsburgh, PA, USA). Then membranes were blocked with 5% non-fat milk (Bio-Rad) in Tris-buffered saline (TBS) for 1 h. Afterward, blots were incubated with biotin-coupled anti-FoxP3 antibody (clone 236A/E7; eBioscience) or antiFoxP3 (ab22510; Abcam, Cambridge, MA, USA) at 4°C overnight. Anti-b-actin and anti-a-tubulin (both from Abcam) antibodies were used as loading controls. Recombinant FoxP3 peptide (ab16809; Abcam) was used to control the antibody specificity. Streptavidin-HRP conjugate (Amersham Pharmacia Biotech Europe) or a-mouse IgG-HRP (Abcam) was then used for 1 h at room temperature. ECL (Pierce) reagents were used to visualize the membranes. Between incubation periods, TBS/0.05% Tween (Fisher Scientific) was used to wash the nitrocellulose membranes. Pre-stained molecular standards (Bio-Rad, New England Biolabs, Ipswich, MA, USA) were used as electrophoresis markers. The densitometry was analyzed by ScionImage or ImageQuant softwares for Windows.
Stimulation of iNKT clones
Round-bottom polystyrene plates (Corning-CoStar Corp.) were coated with 1 lg ml À1 a-CD3 (Exalpha Biologicals Inc., Watertown, MA, USA) in 50 ll per well of PBS at 37°C ; Remel Inc.) and a-GalCer (100 nM a-GalCer, KRN7000; Kirin Brewery, Gunma, Japan) stimulation, the same amount of cells was used as indicated above for 24 h. Phorbol myristate acetate (PMA) (10 ng ml À1 ; Sigma-Aldrich) and ionomycin (500 ng ml À1 ; Sigma-Aldrich) were used for the time course experiment. Anti-CD3 stimulation for time course experiments was performed as described above. Prior to stimulations, NKT clones were cultured without IL-2 in the media for 5 days; cell survival and numbers were assessed by trypan blue exclusion.
In vitro proliferation assays
PBMC were re-suspended in media at a concentration of 13.3 million cells per ml and then pulsed with tetanus toxoid in flocculation units per ml (0.1 Lf ml À1 ) (Massachusetts Department of Health, Boston, MA, USA) or were kept without antigen for 2 h. The pre-stimulated PBMC were further diluted and plated into 96-well plates at 150 000 cells per 200 ll media per well final concentration. Both variations were run at least in duplicate. Following 4 days of incubation at 37°C and 5% CO 2 , 100 ll cRPMI was collected, 0, 5, 20, 40 ll filtered (0.22 lm) supernatant of the CD3-stimulated iNKT cells and fresh cRPMI to a final volume of 200 ll were added to the wells. The cells were incubated for an additional 3 days. On the seventh day, [ 3 H]-methyl-thymidine (Amersham Biosciences, Foster City, CA, USA) was added into each well (1 l Curie per well). After 18-h incubation, counts per minute values were measured on a Wallac 1450 MicroBeta TriLux liquid scintillation and luminescence counter (PerkinElmer Wallac Inc., Gaithersburg, MD, USA).
PBMC (responder cells) were stained with carboxyfluorescein succinimidyl ester (CFSE, 5 lg ml À1 ; Molecular Probes, Eugene, OR, USA) for 10 min in media, and the staining was stopped with 203 amount of ice-cold media. The CFSEstained cells were pulsed, plated and incubated as above. On the fourth day autologous, a-CD3-activated or non-activated washed iNKT cells (10 000 per 20 ll media per well) or supernatants of the activated or non-activated iNKT clones were added. Every condition was done at least in duplicates. On the seventh day, the cell cultures were washed and stained with a-CD4-PE and a-CD8-PECy5 antibodies. The activation or inhibition of responder cells was measured with flow cytometry (Coulter Epics XL) by calculating the ratio of the CFSE low/ CFSE high cells.
Cytokine secretion assay (IL-4, IL-2, IL-10, IFN-c, TGF-b) and cytokine neutralization of in vitro proliferation assays Cytokine production from the supernatants was evaluated by ELISA or Luminex methods. A sandwich ELISA method with a combination of unlabeled and biotin-labeled monoclonal antibodies was used to measure IFN-c and IL-4 (BD Biosciences Pharmingen). Avidin-peroxidase conjugate and 3,3#,5,5#-tetramethylbenzidine substrate (BD Biosciences Pharmingen) were used to develop the assay. IL-10 was measured with a Human IL-10 ELISA kit (eBioscience). IL-2 was measured with a Human IL-2 ELISA Kit (eBioscience) and TGF-b was detected with the Human TGF-b1 DuoSet (R&D Systems, Minneapolis, MN, USA) according to the manufacturers' protocols. For the Luminex assay, a Human Cytokine Lincoplex Kit (Millipore Corporation, Billerica, MA, USA) was used on a Luminex 100 device (Luminex Corporation, Austin, TX, USA).
Supernatants of iNKT cells were complemented with neutralizing a-IL-2 or a-IL-4 or a-IFN-c antibodies (all from Abcam) or a mixture of these antibodies and then the supernatants were applied in the in vitro stimulation assays of PBMC responder cells.
Statistical analysis
Statistical analysis was performed by Microcal Origin (Microcal Software Inc., Northhampton, MA, USA). The effect of treatments was compared with one-way analysis of variance and Scheffe post-hoc tests. Results are presented as mean and all error bars represent the standard error of the mean; P < 0.05 was considered statistically significant.
Results
mRNA and protein expression of FoxP3 in iNKT clones
In our recent study, we characterized and compared the frequencies and cytokine patterns of iNKT subgroups among healthy and diabetic individuals (early onset type 1, late type 1 and type 2 diabetic patients) (18) . Because of the low frequency of iNKT cells in peripheral blood, we used a single-cell cloning procedure (Va24/6B11 double-positive cells) to raise efficient amounts of iNKT cells for in vitro experiments. Following 20 days of culturing, clones were used for RNA and protein isolation. GAPDH was used to confirm the quality of produced cDNA. To verify the sorting and cloning, the iNKT clones were stained again (Va24/Vb11/6B11) and the invariant Va24-JaQ TCR region was checked by reverse transcription (RT)-PCR and sequencing (Fig. 1A) . Staining of the iNKT clones with TCR and CD4/CD8-specific antibodies for flow cytometry analysis verified that the cloning procedure resulted true iNKT clones. All clones were stained to check their clonality before we used them in further experiments (Supplementary Figure 1 is available at International Immunology Online).
Among markers that characterize Treg cells from patients, we chose to measure the expression of FoxP3 transcription factor. We intended to use iNKT clones as a negative control. However, interestingly, we found FoxP3 mRNA products in several cultured iNKT clones (Fig. 1A) derived from healthy individuals. FoxP3 mRNA expression was expressed in all subtypes (CD4+, DN, CD8+) of iNKT clones but variable among the clones. Further, we checked several cell lines (Jurkat human T-cell leukemia, Raji human B-cell lymphoma, THP-1-human acute monocytic leukemia cell line) and PBMC samples along with iNKT clones for FoxP3 mRNA expression (Fig. 1B) . The FoxP3 expression was detectable from whole PBMC and also iNKT cells but not from T, B and monocytic tumor cell lines. The FoxP3 products of iNKT clones were sequenced to prove the RT-PCR specificity.
Besides the FoxP3 expression at the nucleic acid level, we also confirmed the FoxP3 protein expression from iNKT clones (whole cell lysates) by western blot. We found a single band at ;50 kDa (Fig. 1C-E) . To check the specificity of the antibody, we also did western blot with proteins from lysates of PBMC, iNKT clones, recombinant FoxP3 peptide (positive control), lysates of HEpG2 and K562 tumor cell lines (Fig.  1C-E ). An appropriate band was detected in PBMC (Fig.  1C, lane 1) and in iNKT lysates (Fig. 1C, lane 2 and D, lanes 2-5), while no band occurred in lysates of HEpG2 hepatoma and K562 myeloerythroid leukemia cell lines (Fig. 1E, lanes 3  and 4) .
Furthermore, iNKT clones were used in flow cytometry analysis to detect the presence of FoxP3 protein. After surface staining for CD4 or CD8 markers and permeabilization, we stained the cells for FoxP3. All three iNKT sub-populations (CD4+, DN, CD8+) showed various levels of FoxP3 protein expression (Fig. 1F-H) . The most prominent expression was observed in the CD4+ iNKT cell population (Fig. 1F) . Isotype controls were performed to verify the specific FoxP3 staining of iNKT clones (Supplementary Figure 2 is available at International Immunology Online).
FoxP3 mRNA and protein expression in unmanipulated iNKT cells from human peripheral blood During the cloning procedure, recombinant hIL-2 was used to supplement the media, which caused stimulation of lymphocytes and led to changes in protein expression. However, endogenous IL-2 could be produced by the in vitro stimulated cells, which may also cause increased expression of FoxP3. To resolve this, we isolated iNKT cells from unstimulated PBMCs. After co-staining with the 6B11/Va24 antibodies, we sorted iNKT cells ( Fig. 2A) and isolated total RNA from ca. 8000-10 000 iNKT cells. We performed RT and then the RT-PCRs for housekeeping gene product b 2 -microglobulin, Va24-JaQ joining region of TCR and FoxP3 from two PBMC samples (Fig. 2B) . FoxP3 primers produced a weak but solid band. All products were sequenced and proved to have the appropriate sequence identities.
Moreover, we directly stained peripheral blood cells with invariant TCR (6B11)/CD3 markers (Fig. 2C) and then FoxP3 marker after fixation and permeabilization. Isotype control antibodies were applied to avoid non-specific binding. Hierarchical gating revealed clear expression of FoxP3 protein in peripheral blood iNKT cells compared with the isotype control (Fig. 2D) . The FoxP3 expression of iNKT cells was measured from different blood donors as well as the FoxP3 expression of CD4+ CD25+ Treg cells ( Supplementary Figure 3 is available at International Immunology Online) measured from the same blood donors.
Stimulations of iNKT clones result enhanced FoxP3 expression along with T h 1 and T h 2 cytokine production
The mouse and human FoxP3 show a high sequence similarity, but there are differences in function and expression (38, 39) . In our next experiments, iNKT clones were activated with different stimulations, such as a-CD3, PHA, a-GalCer and PMA-ionomycin. Firstly, we checked FoxP3 mRNA level upon stimulation of the TCR (a-CD3 treatment, PHA, Inducible FoxP3 marks the human iNKT cell function 477 The charts represent the mean derived from four independent experiments (mean 6 SEM, *P < 0.05) (A and B). FoxP3 expression changes were monitored over time during a-CD3 and PMA-ionomycin stimulation on mRNA and protein level (C-F). Anti-CD3 stimulation for 24 h generated a continuous increase of FoxP3 mRNA and protein expression that decreased at 48 h, however by PMA-ionomycin stimulation higher mRNA expression appeared as early as 1 h stimulation for a short period, while protein expression with a delay peaked at 24 h (C-F).
a-GalCer). Quantification of relative mRNA level of FoxP3 showed an increase upon stimulation (Fig. 3A-B) . The most striking elevation was observed after anti-CD3 stimulation. Both CD4+ (P = 0.039) and DN (P = 0.033) clones had increased expression of FoxP3 mRNA upon anti-CD3 stimulation, while CD4+ clones showed an increase upon PHA (P = 0.046) and slight non-significant elevation with a-GalCer stimulations and DN cell lines showed moderate non-significant increase upon PHA treatment comparing with media controls (Fig. 3A-B) .
With a-CD3 and PMA-ionomycin stimulations, iNKT clones were analyzed at various time points to observe the dynamic changes over time of FoxP3 expression at mRNA and protein levels. Before treatments, cells were cultured with media without IL-2 for 5 days. During anti-CD3 stimulation, the highest expression of mRNA was observed at 24 h and then it dropped (Fig. 3C) . The protein expression was already detectable at 0 h and increased at 1 h, while the highest protein expression was at 24 h and then decreased (Fig. 3E) . With PMA-ionomycin stimulation, the mRNA expression peaked early at 1 h and then decreased at 4 h (Fig. 3D) , while protein expression appeared slightly at 4 h and then increased, while the highest expression was observed at 24 h and then it dropped at 48 h (Fig. 3F) .
All subtypes of iNKT cells expressed FoxP3 protein upon anti-CD3 stimulation (Fig. 4A-C) , as shown by western blot. FoxP3 protein expression increased within the first 4 h of stimulation in DN and CD8+ clones, while CD4+ clones showed a delayed response after 4 h of stimulation. Flow cytometry experiments were also performed and upon stimulation, elevated levels of FoxP3 protein in iNKT cells were observed. After 24 h stimulation with anti-CD3, higher amounts of FoxP3 protein were detected by intracellular staining (Fig. 4D ) and anti-CD25 surface staining showed an increased expression of IL-2Ra chain (data not shown) compared with non-activated samples.
Along with FoxP3 expression, we followed the cytokine expression profiles of stimulated iNKT subgroups. In the time course experiments, stimulated iNKT clones produced elevated levels of both T h 1 and T h 2 cytokines. Production of IL-2 and IL-4 showed a similar pattern with FoxP3 expression that the highest amount of IL-4 and IL-2 was produced among the 18-21 h time period, while in the case of IL-10, the peak was observed at 24 h. CD8+ clones did not produce IL-10 upon stimulation. All the previous cytokine levels decreased at the 48 h time point. IL-5 and IFN-c production showed a slower response and the highest concentration appeared at 48 h (Fig. 5) .
iNKT cells cause cell proliferation in antigen-specific functional cellular assays iNKT cells can both stimulate and suppress the immune response. In our next experimental set-up, we wanted to address whether the cultured iNKT clones could inhibit or enhance the proliferation of responder cells in vitro. The culture media of both tetanus toxoid antigen-pre-stimulated and unstimulated PBMCs were supplemented with various amounts of supernatant produced by a-CD3-stimulated iNKT clones. This conditioned media caused a significant dosedependent stimulation of the PBMC responder cells Inducible FoxP3 marks the human iNKT cell function 479 independently of their pre-stimulation (Fig. 6A ). Next, we tested whether either the supernatant or iNKT cells themselves can cause proliferation. PBMCs were stained with CFSE and the culture system was supplemented with either non-stimulated/a-CD3-stimulated iNKT cells or their supernatants. The proliferation of responder PBMCs was monitored by flow cytometry (Fig. 6B) . Both the supernatant of iNKT clones and the cells exerted significant activation effects on PBMC. This activation was independent from previous tetanus toxoid antigen stimulation of the PBMC responder cells (Fig. 6C) .
Cytokines released by iNKT cells evoke PBMC proliferation that negatively correlates with FoxP3 expression in iNKT cells
Relating to the in vitro experiments, it is clear that not only stimulated iNKT cells themselves but also their released humoral factors led to proliferation of PBMC responder cells. To address which cytokines could correspond to the observed stimulation, we added cytokine neutralization antibodies (a-IL-2, a-IL-4, a-IFN-c separately or their mixture) to the culture system. The addition of anti-IL-2 antibody to cultures reduced these stimulatory effects caused by the supernatants of CD4+ or DN iNKT clones (Fig. 7A) . Applying a-IL-4 and a-IFN-c antibodies, we observed no appreciable inhibitory effect (data not shown).
We then wanted to clarify if there is any connection between the iNKT-mediated proliferation and their FoxP3 protein expression. Interestingly, correlation analysis revealed that the observed stimulation effect showed a strong inverse relationship with the FoxP3 protein content of the iNKT clones as analyzed by western blot (R 2 : 0.9354, P = 0.0002) (Fig. 7B) . Regression analysis between IL-2 cytokine production and FoxP3 expression of iNKT cell clones revealed a non-significant trend for negative correlation (R 2 : 0.5354, P = 0.07) (Fig. 7C ).
Discussion
One important component of peripheral tolerance is lymphocytes with regulatory functions, including CD4+ CD25hi+ Treg cells and iNKT cells. These lymphocyte subsets are important in controlling autoreactivity and maintaining immune homeostasis, overall regulating the immune response (4, 8, 29) . iNKT cells are a small heterogenous group of lymphocytes that recognize glycolipid antigens. Their low frequency, tissue redistribution or changed activation may be associated with numerous pathological conditions, such as infectious and chronic organ-specific or systemic inflammatory disorders (13, 14, 40, 41) . The most accessible way to analyze the frequency and function of iNKT cells in humans is to use peripheral blood, but it is not always suitable, due to the low cell number, variable frequency and heterogeneity (28, (42) (43) (44) (45) .
The regulatory functions of iNKT cells are mainly described by their cytokine production patterns. In our approach, we looked for key regulatory markers in Treg biology such as FoxP3 whose expression suggested being largely limited to CD4+ CD25hi+ Treg cells. Data published so far indicated that there is no expression of FoxP3 in mouse or human iNKT cells (46, 47) ; however just recently, FoxP3 expression was detected in mouse and human iNKT cells (48) . In this study, iNKT cells were generated by TGF-b among other soluble factors (48) . In our experiments, we investigated human iNKT cells and we aimed-after a primary observation of FoxP3 mRNA expression in iNKT cells-to extensively study FoxP3 marker expression in human iNKT cells and its correlation with iNKT cell function. In order to examine regulatory marker expression patterns, we raised human iNKT clones. Surprisingly, we found FoxP3 mRNA and protein expression in cultured human iNKT clones. Overall, the FoxP3 expression was detectable in all three subgroups of NKT cells (CD4+, CD8+, DN). By contrast, FoxP3 mRNA and proteins were not detectable in commonly used human tumor cell lines (e.g. Jurkat, Raji, HEpG2), which were consistent with other observations (49) .
The structure of FoxP3 protein appears to be well conserved among species; however, the expression and function of FoxP3 is rather different in humans when compared with mice (12) . In contrast to the mouse, human FoxP3 gene codes two isoforms of the mature molecule and several lines of evidence revealed that human FoxP3 molecule is upregulated in naive CD4+ T cells after stimulation either by antigen-dependent or independent mechanisms (12, 38, 50, 51) . In our experimental set-up, iNKT clones were stimulated with various compounds such as a-CD3, PHA, a-GalCer and PMA-ionomycin, among which a-CD3 increased most strongly the FoxP3 mRNA expression; this effect was verified on protein level in all three subsets of iNKT cells. It is known that stimulation through TCR (a-CD3/a-CD28, PHA) increases the expression of FoxP3 in humans (38, 50, 52) . Since a-GalCer is a crucial exoantigen in iNKT cell stimulation and characterization, we tested whether a-GalCer challenge causes any change in FoxP3 expression. CD4+ iNKT clone clearly showed an up-regulated FoxP3 expression at the mRNA level, but it did not occur in the DN clone. Recent data suggest that iNKT expansion after a-GalCer treatment is highly donor dependent (53) . Here, we suggest that The counts per minute readouts were obtained from 10 separate wells for each condition (with and without antigen). The figure represents the means derived from 10 iNKT clones from two individuals (mean 6 SEM, **P < 0.01; ***P < 0.001). Labeling PBMC responder cells with CFSE, we monitored the activated cells (A) and resting (R) population after adding CD4+ but CFSE-negative iNKT cells to this in vitro culture system (B, representative example from four clones of two donors). Calculating the ratio of proliferating cells (C), we observed significant cell expansion after adding activated iNKT supernatant or iNKT cells. Data represent the means derived from four separate experiments and measurements were done in duplicates (mean 6 SEM, *P < 0.05; **P < 0.01; ***P < 0.001).
Inducible FoxP3 marks the human iNKT cell function 481 a-GalCer could differently activate subtypes of iNKT cells especially if these cultured iNKT cells were biased with previous IL-2 treatment (54).
Moreover, a new interesting observation was the increased expression of FoxP3 mRNA and protein after PMA-ionomycin stimulation. To our best knowledge, our study is the first to observe FoxP3 induction upon PMA-ionomycin stimulation in lymphoid hemopoetic cells. Recent novel data claim that megakaryocytes express FoxP3 factor and PMA stimulation dose dependently increase the FoxP3 expression (55) .
Another question concerned how FoxP3 expression corresponds to the function of iNKT cells. Knowledge of suppressor or stimulatory activity of iNKT cells is scarce. Most data showed suppressor activity of iNKT cells against effector cells (56) . This effect is maintained by clusters of T h 1 and T h 2 cytokines released from activated iNKT cells. We applied either the supernatant of iNKT cells or iNKT cells to responder cells to verify the stimulatory/inhibitory effect. In our experiments, we observed stimulation effect of cultured iNKT cells on responding cells. Supernatants from stimulated iNKT cells caused a dose-dependent proliferation of responder PBMCs, due to their cytokine content, largely in an IL-2-dependent manner. Moreover, iNKT cells also caused significant PBMC expansion; it could be due to their cytokine production by close contact with responder cells or by direct cell-cell connections. Hence, with anti-IL-2 antibody, the thymidine incorporation decreased to the baseline levels in most samples. This effect was also observed when applying the supernatant of DN iNKT clones (Fig. 7A) , and it is known that DN clones are prominently producing T h 1 cytokines (57, 58) .
One of the molecular functions of FoxP3 is to suppress expression of IL-2 and additional cytokines and to contribute to the anergic states of Treg cells. Our data support the notion that FoxP3 suppresses IL-2 expression in iNKT cells. However, the negative correlation was not significant, leaving open the possibility that other cytokines are also targets for FoxP3-mediated transcriptional repression. FoxP3 expression of iNKT cells and their proliferation-inductive capacity shows a strong negative correlation supporting that FoxP3 controls cytokine production. There is evidence of FoxP3 binding with nuclear factor of activated T cells, which prevents the association with activator protein-1 and contributes to inhibit IL-2 gene expression (59) (60) (61) . Despite intensive research, the molecular mechanisms of FoxP3+ Treg-suppressive function are not entirely clear. Depending on the experimental system, cell surface-expressed inhibitory molecules, including TGF-b, CTLA-4, lymphocyte activation gene-3 and the PD-1/programmed cell death ligand 1 (PD-L1) pathway, have been implicated to play role in Treg inhibitory function (62) .
Recently, it has been reported that FoxP3 is expressed in various epithelial cells (breast, lung, prostate) and acts as a tumor suppressor gene (63, 64) . It is also expressed in various human tumor cell lines (65, 66) . Moreover, an extensive study showed that FoxP3 molecule is expressed in megakaryocytes and involved in platelet function in both mice and humans (55) . These lines of evidence challenge the view that FoxP3 would be a nTreg/iTreg cell-specific marker at least in humans. FoxP3 transcription factor seems to have a broad important role in cellular functions, which is not exclusively restricted to Treg cells (51, 67, 68) .
Our novel data show FoxP3 effect on iNKT cell function. These results support the notion that FoxP3, similarly to the other Treg populations, plays a key role in the regulatory function of the iNKT cell population. Supplementary Figures 1-3 are available at International Immunology Online.
Supplementary data
